Format

Send to

Choose Destination
Medicine (Baltimore). 2015 Feb;94(6):e494. doi: 10.1097/MD.0000000000000494.

Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses.

Author information

1
From the Marmara University, School of Medicine, Department of Rheumatology Istanbul (FA-O, AK, HD); Selçuk University, School of Medicine, Department of Rheumatology Konya (SY); Pamukkale University, School of Medicine, Department of Rheumatology Denizli (AB, VÇ); Gaziantep University, School of Medicine, Department of Rheumatology Gaziantep (GK, BK, AMO); Kocaeli University, School of Medicine, Department of Rheumatology Kocaeli (AY, AÇ); Gulhane Military School of Medicine, Department of Rheumatology Ankara (MÇ, SY, SP); Çukurova University, School of Medicine, Department of Rheumatology Adana (FY, EE); Osmangazi University, School of Medicine, Department of Rheumatology Eskişehir (ŞYB, TK); Hacettepe University, School of Medicine, Department of Rheumatology Ankara (EB, UK, ÖK); Uludağ University, School of Medicine, Department of Rheumatology Bursa (BNC, YP); Ankara Numune Training and Research Hospital, Department of Rheumatology, Ankara (AO); Sütçü İmam University, School of Medicine, Department of Rheumatology, Kahramanmaraş (GYÇ); Bilim University, School of Medicine, Department of Rheumatology, Istanbul (YÇ); Hitit University Medical Faculty, Department of Rheumatology, Çorum (YK); and Ondokuz Mayıs University, School of Medicine, Department of Rheumatology, Samsun, Turkey (MS).

Abstract

Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively.Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired.VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments.We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.

PMID:
25674739
PMCID:
PMC4602744
DOI:
10.1097/MD.0000000000000494
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center